Neurocrine Biosciences

NBIX · Nasdaq · United States

Share price · NBIX

$162.86+8.63 (+5.60%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.6M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NBIX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+13.4%
  2. 12 Aug 2026-3.4%
  3. 31 Jul 2026-10.1%
  4. 28 Jul 2026+3.6%
  5. 3 Jun 2026+6.6%
  6. 6 May 2026+8.9%
  7. 12 Feb 2026-10.4%
  8. 26 Nov 2025+5.6%

Share of unusual movement by asset

For each asset, the share of NBIX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Crinecerfont
events and moves
115%
Valbenazine (Ingrezza)
events and moves
223%
diazoxide choline (Vykat XR)
events and moves
5shown from 8 days
Osavampator
events and moves
4shown from 8 days
Direclidine
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—13%
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—34%

Assets

(6 total)
6Total Assets
3Approved
2Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
CRF type 1 receptorSmall molecule
Congenital Adrenal Hyperplasia
Approved
KATP channelSmall molecule
Prader-Willi Syndrome
Valbenazine(Ingrezza)
Approved
vesicular monoamine transporter 2 (VMAT2)Small molecule
Tardive DyskinesiaHuntington's Disease
Huntington's Disease Chorea
Phase 3
Muscarinic M4 receptorSmall molecule
Schizophrenia
Phase 3
AMPA receptor (positive allosteric modulator)Small molecule
Major Depressive Disorder
Phase 2
Muscarinic M1 and M4 receptors (agonist)Small molecule
Schizophrenia

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
July 2027 (3)
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2027-07 · NCT06786624 · CT.gov ↗
What to watch
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2027-07 · NCT06911112 · CT.gov ↗
What to watch
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2027-07 · NCT06963021 · CT.gov ↗
What to watch
August 2027 (1)
NBI-1117570Phase 2Schizophrenia
Est. primary completion 2027-08 · NCT07288333 · CT.gov ↗
What to watch
October 2027 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2027-10 · NCT06963034 · CT.gov ↗
What to watch
November 2027 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2027-11 · NCT07105098 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
CrinecerfontPhase 3Congenital Adrenal Hyperplasia
Est. primary completion 2028-01 · NCT07947368 · CT.gov ↗
What to watch
February 2028 (1)
DireclidinePhase 2Bipolar I Disorder, Mania
Est. primary completion 2028-02 · NCT07288320 · CT.gov ↗
What to watch
April 2028 (1)
Valbenazine · IngrezzaPhase 3Chorea, Huntington
Est. primary completion 2028-04 · NCT06312189 · CT.gov ↗
What to watch
July 2028 (1)
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2028-07 · NCT07196501 · CT.gov ↗
What to watch
2029 (2)
May 2029 (1)
OsavampatorPhase 3Major Depressive Disorder
Est. primary completion 2029-05 · NCT06966401 · CT.gov ↗
What to watch
July 2029 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2029-07 · NCT07227818 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
DireclidinePhase 3Schizophrenia
Est. primary completion 2031-12 · NCT07114874 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 April 2026Withdrawaldiazoxide cholineSoleno withdraws EU marketing authorisation application for Viokat (diazoxide choline)
EU, EMA · Soleno Therapeutics · Source ↗
22 December 2025Topline resultValbenazine (Ingrezza)KINECT-DCP Phase 3 misses primary and key secondary endpoints
Neurocrine Biosciences · Source ↗
December 2025Topline resultValbenazineKINECT-DCP Phase 3 (NCT05206513) did not meet its primary or key secondary endpoints
Neurocrine Biosciences · Source ↗
28 May 2025Topline resultDireclidinePhase 2 schizophrenia study results
22 May 2025Filing accepteddiazoxide cholineEMA validates MAA for diazoxide choline prolonged-release tablets
EU, EMA · Source ↗
27 February 2025Topline resultValbenazineKINECT-PRO Phase 4 top-line patient-reported outcome data
13 December 2024ApprovalCrinecerfontFDA approves CRENESSITY for classic CAH
US, FDA · Source ↗
23 April 2024Topline resultNBI-1065845 (osavampator)SAVITRI Phase 2 topline: positive on MADRS
Neurocrine Biosciences · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.1B$352M$648M+ $96M short-term inv.—$395M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$959M$327M$339M+ $57M short-term inv.—$136M operating cash flowreport ↗
2026-Q1$815M$296M$275M+ $1.0B short-term inv.—$146M operating cash flowreport ↗
2025-Q3$795M$250M$348M+ $775M short-term inv.—$228M operating cash flowreport ↗
2025-Q2$688M$244M$272M+ $712M short-term inv.—$102M operating cash flowreport ↗
2025-Q1$573M$263M$202M+ $749M short-term inv.—$65M operating cash flowreport ↗
2024-Q3$622M$195M$357M+ $879M short-term inv.—$158M operating cash flowreport ↗
2024-Q2$590M$191M$148M+ $899M short-term inv.—$65M operating cash flowreport ↗
2024-Q1$515M$159M$404M+ $814M short-term inv.—$130M operating cash flowreport ↗
2023-Q3$499M$142M$302M+ $801M short-term inv.—$212M operating cash flowreport ↗
2023-Q2$453M$146M$168M+ $817M short-term inv.—$180M operating cash flowreport ↗
2023-Q1$420M$140M$112M+ $791M short-term inv.$77M-$125M operating cash flowreport ↗
2022-Q3$388M$108M$220M+ $587M short-term inv.—$99M operating cash flowreport ↗
2022-Q2$378M$136M$171M+ $485M short-term inv.$17M$138M operating cash flowreport ↗
2022-Q1$311M$102M$278M+ $395M short-term inv.—-$41M operating cash flowreport ↗
2021-Q3$296M$93M$314M+ $455M short-term inv.—$62M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.9B$1.0B$721M+ $767M short-term inv.—$783M operating cash flowreport ↗

Neurocrine reported full-year 2025 total revenues of $2,860.5M, up 21.4% YoY. GAAP R&D expense was $1,015.7M, up 38.9% YoY, and the company ended the period with $721M in cash and equivalents and GAAP net income of $478.6M.

For 2026, Neurocrine guided INGREZZA net product sales to $2.7–$2.8B, GAAP R&D to $1,200–$1,250M, GAAP SG&A to $1,375–$1,400M, and GAAP and non-GAAP IPR&D to $20M. Pipeline developments include Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, initiation of a Phase 2 study of NBI-1065890 in tardive dyskinesia, and expansion of the CRF platform into metabolic diseases including obesity.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.4B$731M$241M+ $843M short-term inv.—$595M operating cash flowreport ↗
2023-FY$1.9B$565M$259M+ $781M short-term inv.—$390M operating cash flowreport ↗
2022-FY$1.5B$464M$271M+ $726M short-term inv.—$339M operating cash flowreport ↗
2021-FY$1.1B$328M$344M+ $371M short-term inv.—$257M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 54 sales ($79.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17LYONS GARY A · directorOption exercise15,000$53.64$805KForm 4
2026-11-17LYONS GARY A · directorOpen-market sale1,200$163.11$196KForm 4
2026-11-17LYONS GARY A · directorOpen-market sale4,011$163.94$658KForm 4
2026-11-17LYONS GARY A · directorOpen-market sale5,689$165.15$940KForm 4
2026-11-17LYONS GARY A · directorOpen-market sale4,100$165.90$680KForm 4
2026-11-17LYONS GARY A · directorOption exercise (derivative)15,000——Form 4
2026-11-04ROBERTS EIRY · Chief Medical OfficerAward / grant (derivative)8,314——Form 4
2026-11-04ROBERTS EIRY · Chief Medical OfficerAward / grant (derivative)1,506——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 687 reporting institutions held 99.4M shares ($12.8B, 98.2% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.13,385,607$1.8B
2Dodge & Cox5,461,037$719.4M
3JPMORGAN CHASE & CO5,442,067$700.5M
4AQR CAPITAL MANAGEMENT LLC4,938,967$650.7M
5VANGUARD PORTFOLIO MANAGEMENT LLC4,726,344$622.6M
6VANGUARD CAPITAL MANAGEMENT LLC4,511,904$594.4M
7STATE STREET CORP4,354,526$573.7M
8TWO SIGMA INVESTMENTS, LP3,060,570$403.2M
9RENAISSANCE TECHNOLOGIES LLC2,418,897$318.7M
10GEODE CAPITAL MANAGEMENT, LLC2,136,672$280.8M
11BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,493,813$196.8M
12WELLINGTON MANAGEMENT GROUP LLP1,389,539$183.1M
13Vestal Point Capital, LP1,250,000$164.7M
14MILLENNIUM MANAGEMENT LLC1,247,447$164.3M
15NORTHERN TRUST CORP1,242,830$163.7M